Retatrutide

Retatrutide – GLP-1/GIP/GCGR triple agonist

🧪 What is Retatrutide?

Retatrutide is an innovative peptide triple agonist that simultaneously activates the GLP-1, GIP and GCGR receptors. Suitable for subcutaneous administration once a week, it promotes significant weight loss, regulates appetite, improves insulin sensitivity and reduces liver fat.

GLP-1 – controls appetite and improves insulin secretion

GIP – improves insulin response after meals

GCGR – activates lipolysis and increases energy expenditure

With a plasma half-life of approximately 6 days, Retatrutide is administered subcutaneously once a week, which makes it convenient and effective for long-term use.

⚙️ How does Retatrutide work?

Retatrutide acts through a triple synergistic effect:

Reduces hunger and food intake

Stimulates metabolism

Improves glucose and lipid metabolism

Contributes to long-term and sustainable weight loss

📊 Clinical trials (Phase I, II, III) and results

Phase Aim Results

I Safety and pharmacokinetics Confirmed weekly half-life, good tolerability

II. Efficacy in obesity Up to 24.2% weight loss, improvement in HbA1c, HOMA-IR

III Long-term safety Under investigation in diabetes and MASLD

🏆 Benefits of Retatrutide

✔️ Loss of up to 24% of body mass

✔️ Improved cholesterol and triglyceride levels

✔️ Reduced appetite and hunger control

✔️ Reduced liver fat by up to 82%

✔️ Convenient weekly subcutaneous injection

✔️ Documented safety in all clinical phases

⚠️ Possible side effects of Retatrutide

Retatrutide, like other GLP-1/GIP/GCGR agonists, may cause some side effects, especially at the initiation of treatment or when the dose is increased. Most effects are temporary, mild, and reversible.

🔸 Most common reported side effects:

Nausea, the most common side effect, usually mild to moderate, decreases with adaptation. Vomiting is possible at the beginning of treatment or when the dose is rapidly increased. Diarrhea or constipation can be temporary changes in digestion, often resolving with dose adjustment. Fatigue and weakness are possible in the first few weeks. Increased heart rate during exercise.

Important: Most symptoms disappear with time and with dose adjustment. At higher doses, side effects may be more severe.

Recommendation: For safety and optimal results, apply under the supervision or in consultation with a qualified specialist in the field of peptide therapies.

✅ Why choose Retatrutide:

Retatrutide is among the most promising multireceptor peptides, with proven effects on obesity, metabolic syndrome and hepatic steatosis. Its high efficacy and convenient dosage make it a suitable choice for studies targeting complex therapy.

The product is provided for research purposes only!